The work of the Indiana Biosciences Research Institute (IBRI) reflects the dynamic and evolving role of innovators in the biomedical field and uniquely positions us alongside industry and academia to advance science and drug discovery, and deliver meaningful outcomes for patients.
Science is advancing at a rapid pace. Unprecedented access to novel genetic and genomic analyses of disease tissues along with human-derived models for preclinical experimental work have opened new ways to study disease and pursue novel interventions.
These approaches have led to a better molecular understanding of disease and patient heterogeneity, in addition to new therapeutic hypotheses to explore. It is ultimately our goal to return these findings to patients in the form of novel therapies and diagnostics that improve disease outcomes.
We therefore envision translational science as a cyclical process of continual learning, applied research and drug discovery that begins and ends with the patient. Through the lens of a research institute, there are multiple entry points from diverse scientific disciplines for insights, hypothesis generation and medical innovation leading to potential breakthroughs.
The four foundational areas of scientific focus at the IBRI will provide us the core talent and capability to pursue translational science and drug discovery in this new patient-centric framework.